On Tuesday, XOMA Corp (NASDAQ:XOMA)’s shares declined -3.77% to $3.32.
XOMA Corp (XOMA) declared gevokizumab will be tested in a Phase 2 study in patients with Type 2 diabetes and diabetic kidney disease, clinically referred to as diabetic nephropathy. The international, multicenter, randomized, double-blind, parallel-group, placebo-controlled study is predictable to enroll 370 patients who will be randomized to receive gevokizumab or placebo for 52 weeks.
The primary objective of this study is to detect the existence of an overall dose-response relationship of subcutaneously dosed gevokizumab on the measured glomerular filtration rate (mGFR), an accurate measure of kidney function, at Week 52. The study also will determine gevokizumab’s effect on a number of biological biomarkers assessing kidney function. Servier will fully sponsor the study’s execution and cost.
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The companys lead product candidate comprises gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçets disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, in addition to diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis. I
IGI Laboratories, Inc. (NYSEMKT:IG)’s shares dropped -3.75% to $7.95.
IGI Laboratories, Inc. (IG) declared its financial results for the first quarter ended March 31, 2015.
First Quarter 2015 Highlights
- Total revenues of $10.7 million in the first quarter of 2015, an enhance of 56% over the same quarter in 2014.
- Total net revenues generated from the sale of IGI label generic topical pharmaceutical products for the three months ended March 31, 2015 and 2014 of $8.1 million, and $2.9 million, respectively.
- Gross profit for the three months ended March 31, 2015 equaled 53% as contrast to 42% in the same period of 2014.
- IGI filed one Abbreviated New Drug Application (ANDA), in the first quarter of 2015 with the U.S. Food and Drug Administration (FDA), and one ANDA on April 28, 2015 .
- Operating income was $1.1 million in the first quarter of 2015 contrast to $0.2 million in the same period in 2014.
IGI Laboratories, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets topical formulations in the United States. It sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms under IGI label.
At the end of Tuesday’s trade, Biogen Inc (NASDAQ:BIIB)‘s shares dipped -3.75% to $374.98.
Biogen Inc (BIIB) declared that it will present at the 40th Annual Deutsche Bank Health Care Conference. The webcast will be live on Wednesday, May 6, 2015 at 11:20a.m. ET. To access the live webcast, please visit Biogen’s Investors section at www.biogen.com. An archived version of the webcast will be accessible for 14 days following the presentation.
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally.
Parker-Hannifin Corporation (NYSE:PH), ended its Tuesday’s trading session with -3.69% loss, and closed at $120.28.
Parker-Hannifin Corporation (PH) declared that its Board of Directors has declared a regular quarterly cash dividend of 63 cents per share of common stock to shareholders of record as of May 8, 2015. The dividend is payable June 5, 2015.
This is the company`s 260th successive quarterly dividend. Parker has raised its annual dividends paid to shareholders for 59 successive fiscal years, among the top five longest-running dividend-enhance records in the S&P 500 Index.
Parker-Hannifin Corporation manufactures and sells motion and control technologies and systems for various mobile, industrial, and aerospace markets worldwide. It operates through two segments, Diversified Industrial and Aerospace Systems.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
